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Abstract 
 
Cisplatin (cisp) is the first line chemotherapeutic agent for several cancer diseases which 
can cause significant side effects and cellular resistance. Combination-chemotherapy treatment (co-
chemotherapy) was reported to be able to reduce cisp effects. Therefore, this study was carried 
out to investigate the cytotoxic activity of ethyl acetate fraction of C. sappan (EFC) in combination 
with cisp by observing apoptosis induction and cell cycle profile. Cytotoxic activity was evaluated 
by MTT assay. Cell cycle and apoptosis analysis were performed using flow cytometry and p53 
expression was analyzed using immunocytochemistry. EFC performed cytotoxic effect on HeLa 
cells by showing morphological changes such as cell shrinkage, rounding and decreasing of cells 
viability in concentration dependent manner, giving IC50 value of 65 μg/mL. Combination of EFC 
and cisp in low concentration decreased cell viability into 36.86%. Further assay indicated that this 
combination caused redistribution of cell cycle arrest in G1 and S phases through p53 stabilization 
in nucleus. However, that mechanism was not followed by apoptosis. These results provide 
evidence to support EFC development as the enhancer of cisp effect, by improving its cytotoxicity 
on HeLa cells. EFC increases HeLa cells sensitivity to cisp through G1 and S cells’ arrest depending 
on p53 expression.   
 
Keywords: co-chemotherapy, EFC, cervix cancer HeLa cells, p53, G1 and S arrest.        
 
INTRODUCTION 
 
Cervical cancer is the third most common 
disease among women worldwide (Jemal, et al., 
2011), which 70% of its occurrence is caused by 
HPV infection (Castellsagué, 2008). Globally, 80-
85% of death occurs in low- and middle-economic-
income countries. The statistics estimation was made 
based on Globocan 2008 which state that the 
incidence of cervical cancer is increasing every year, 
with global estimation of new cases expected to 
increase 2% per annum to 770,000 new cases by 
2030 (Forman, et al., 2012). There are several ways 
to treat cervical cancer, including surgery, radiation 
therapy, chemotherapy, and combination of those 
treatments. To date, chemotherapeutic agent is the 
most common treatment (Martin, et al., 2013; Leaver 
and Labonte, 2010). 
Cisplatin (cisp) is the first chemotherapeutic 
agent from platinum (Jamieson and Lippard, 1999). 
This agent caused many side effects, such as severe 
nausea and vomiting, acute and chronic 
nephrotoxicity, anemia (Miller, et al., 2010; Rabik 
and Dolan, 2007), acute cochlear toxicity 
(ototoxicity) (Mukherjea and Rybak, 2011) and also 
developed cells resistance (Sirichanchuen, et al., 
2012). Some of natural compounds were known as 
cytotoxic agent and can be combined with 
chemotherapeutic agent. Therefore, cisp’s side 
effects and cellular resistance caused by cisplatin can 
be reduced using chemotherapeutic combination 
with natural agent by decreasing of cisplatin uses 
(Zhang, et al., 2011; Zhao, et al., 2004). 
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Herbal medicines used in nutrient 
supplements as anti-cancer and anti-inflammatory 
agents give benefit for patients (Ho, et al., 2002) to 
overcome side effects and drug resistance (Zhang, et 
al., 2011). The heartwood of Caesalpinia sappan has 
been used traditionally for medical treatment in Asia, 
consumed as a drink or a dye
 
(Badami, et al., 2004). 
Previous studies showed that C. sappan extract 
(Ueda, et al., 2002) and its isolated compounds, 
brazilin and brazilein, potentially exhibited 
antitumor activity on several rodents and tumor 
cancer cells (Ren, et al., 2011; Yen, et al., 2011), but 
not on normal epithelial cells
 
(Lee, et al., 2010). The 
main constituent of C. sappan, brazilin, can be 
oxidized by air and light to produce brazilein that is 
soluble in ethyl acetate
 
(Kim, et al., 1997). 
Therefore, in this study, the effects of EFC-single 
treatment and in combination with cisp on HeLa 
cells were determined. Observation was done by 
observing cell viability, apoptosis induction, and cell 
cycle progression. Expression of p53 protein level 
was also investigated. More research in field of 
science will help for further explore the effectiveness 
and safety approaches, as both agents in 
conventional treatment and herbal medicine.      
  
METHODS 
 
Preparation of EFC  
Caesalpinia sappan heartwood powder was 
obtained from Balai Besar Penelitian dan 
Pengembangan Tanaman Obat dan Obat Tradisional 
(B2P2TOOT), Tawangmangu, Indonesia. C. Sappan 
wood was extracted with methanol, evaporated, and 
partitioned with n-hexane and ethyl acetate by 
liquid-liquid extraction. Ethyl acetate fraction was 
evaporated by using rotary evaporator to get the 
residue as EFC. The dried fraction was re-solubilized 
in dimethyl sulfoxide (DMSO) before used as 
treatment sample. Cisplatin (Wako, ≥ 98% HPLC, 
Japan, CAS No.033-20091) was used as 
chemotherapeutic agent.  
 
Chemicals and reagents  
DMEM (Dulbecco’s Modified Eagle Media, 
low glucose), FBS (Fetal Bovine Serum), 
penicillin/streptomycin, fungizone were purchased 
from Gibco (Invitrogen, USA). MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide), PI (Propidium Iodide) (minimum 95% 
(HPLC) were purchased from Sigma (Sigma-Aldrich 
Co., St. Louis, MO, USA). DMSO (99.5% pro GC, 
Sigma Aldrich Chemie GmBH, Steinheim, 
Germany), trypsin-EDTA (Gibco, Invitrogen, 
Canada), FITC-Annexin V Apoptosis Detection Kit 
(Biovision, USA), Triton-X (triton X-100 for GC, 
E.Merck, 64271, Darmstadt, Germany). SDS 
(Sodium Dodecyl Sulphate), HCl were purchased 
from Merck, Germany. RNase was obtained from 
Lab. Animal Sciences, NAIST, Japan. All other 
chemicals were used under analytical grade.       
 
Cell culture  
HeLa cells were obtained from Prof. Masashi 
Kawaichi, Laboratorium of Gene Function in 
Animal, Graduate School of Biological Science, 
Nara Institute of Science and Technology (NAIST), 
Japan. Cells were maintained in DMEM-low 
glucose, supplemented with 10% (v/v) FBS, 1.5% 
(v/v) penicillin-streptomycin, and 0.5 % (v/v) 
fungizone. Cells were incubated at 37˚C and 5% 
CO2. 
 
MTT assay 
HeLa Cells were grown 12x10
3 
onto 96-well 
plates before being exposured to drug treatment. For 
cell viability assay, cells were treated for 24 h with 
increasing concentration of EFC-single treatment (0, 
30, 40, 50, 60, 70, 80, 90 μg/mL). Combination 
treatment was done using both of EFC and cisp, 
incubated for 24 h. As negative control, the cells 
were only treated with growth medium. At 100 µL 
media containing MTT (0.5 mg/mL) was added to 
each well then incubated for 3 h at 37˚C. The 
reaction was stopped by dilution with 10% (w/v) 
SDS in 0.01 M HCl, then continued by incubation 
for overnight. The absorbance was determined by 
using ELISA reader (Bio-Rad microplate reader 
Benchmark, serial no. 11565, Japan) at λ 595 nm as 
previously described with some modification 
(Mosmann, 1983).  
 
Flow cytometry  
FACS analysis was carried out to investigate 
apoptosis quantification and cell cycle distribution. 
Around 5x10
5
 cells/well were grown in 6-well plates 
and cells were treated with EFC, cisp, and 
combination of both compounds for 24 h. 
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Trypsinized adherent cells were collected and were 
prepared for detection. Cell apoptosis was detected 
by using a FITC-Annexin V Apoptosis Detection Kit 
(Biovision, USA). Then, apoptosis was analyzed by 
flow cytometry (BD FACS-Calibur, USA).     
For cell cycle analysis, the trypsinized 
adherent cells were collected and detected by adding 
flow cytometry reagents (25µL PI, 2.5µL RNase, 
0.5µl Triton-X in 500µL PBS), followed by 
incubation at room temperature for 10 minutes in the 
dark. The cell suspension was transferred into a flow 
cytometer tube and its cell cycle profile was read 
using flow cytometry. The cell cycle profile was 
analyzed by ModFit LT 3.0.  
       
Immunocytochemistry 
Immunocytochemistry was developed 
(Cozmei, et al., 2002) with some modifications. 
HeLa cells were grown with the density of 5x10
4
 
cells/cover slip in 24-well plate for 24 h prior to 
treatment of EFC, cisp, and combination of both. 
Cells were treated for 15 h and then fixed with cold 
methanol for 10 minutes and washed twice using 
PBS and sterile water. Cells were blocked with H2O2 
and then pre-diluted blocking serum was added, 
continued with incubation for 10 minutes. Cells were 
washed using PBS and incubated with primary 
monoclonal antibody anti-p53 (mouse monoclonal 
anti-p53 antibody, BioGenex) overnight. Cells were 
washed using PBS, then universal detection kit was 
added (Star Trek Universal HRP Detection Kit, Ref 
STUHRP 700L10-KIT, Biocare Medical). Cells 
were then incubated with biotinylated universal 
secondary antibody for 20 minutes, followed by 
streptavidin-enzyme horse radish peroxidase for 10 
minutes. Substrate solution chromogen 3,3’-
diaminobenzidine (DAB) was exposed for 10 
minutes and cells were counterstained with Mayer’s 
Haematoxylin (Dako) for 1 minute. Then, cells were 
fixed with ethanol and xylol. Between each 
immunostaining step, cells were washed briefly in 
PBS pH 7.4. Negative controls were prepared by 
replacing the primary antibody with PBS. The p53 
expression on the cells was observed by binocular 
microscope (Nikon YS 100, Japan).       
      
 
 
 
Statistical analysis 
Single and combinational cytotoxicity assay:  
IC50 value was calculated by equation 
y=Bx+A acquired from linear regression between 
concentration and % cell viability. IC50 is 
concentration inhibiting 50% cell proliferation. Cell 
viability was calculated with the formula (Meiyanto, 
et al., 2011):  
 
    
 
The datum were performed as average ±SE from 
triplicate (n = 3) experiments.   
Cell viability and p53 expression were 
statistically analyzed using one way ANOVA and 
statistical significance was estimated by using Tukey 
HSD. Statistical significance was determined at 
p<0.05.  
 
RESULT 
 
Cytotoxic EFC and Its Combination with 
Cisp on HeLa cells  
Cytotoxicity assay was used to evaluate the 
potential of EFC cytotoxicity on HeLa cells. 
Furthermore, IC50 value was acquired as the 
parameter of EFC concentration to inhibit 50% HeLa 
cells’ growth. Fig. 1 shows the effect of EFC to cell 
viability for 24 h treatment. EFC caused inhibition 
on cell growth in a concentration-dependent manner 
(Fig. 1A). We suggest that EFC was found to be 
cytotoxic on HeLa cells with IC50 value of 65±1.5 
µg/mL. This fraction exhibited potent cytotoxicity 
(IC50 ≤ 100 µg/ml) (Prayong, et al., 2008). Treated 
cells showed cytotoxic effect with changes in cell 
morphology and the decrease of cell viability. Viable 
cells exhibited epithelial shape, but after being 
treated with certain concentration of samples, the 
cells exhibited cell shrinkage and rounding (Fig. 
1B). 
Cisp performed cytotoxic activity on HeLa 
cells with IC50 value of 16 µM (data not showed). 
IC50 value was then used to determine the 
concentration in combinational treatment that is 
concentration lower than IC50 value. Various  
 
 
x 100% % Cells viability =  
Treated cells abs – medium control abs 
Cells control abs – medium control abs 
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concentrations of cisp (2, 4, 8 µM) were combined 
with 28 µg/mL EFC. Fig. 2 sections confirm that 
combinational treatment performed morphological 
changes and caused decrease of the cells number. 
Cell viability measurement of the combination group 
(EFC combined to cisp) was considered significantly 
different compared to cisp-single treatment group 
(p<0.05). At 8 µM  cisp in combination with 28 
µg/mL EFC decreased significantly HeLa cells’ 
viability compared to 2 and 4 µM cisp (p<0.05). 
There was approximately 63% decrease in HeLa 
cells’ viability treated by 28 µg/mL EFC combined 8 
µM cisp for 24 h.  Cell viability acquired from single 
treatment of EFC and cisp above 100% was 
considered as 100%. Therefore, both low-
concentration of EFC and cisp showed no inhibitory 
effect on HeLa cells. Whereas, combination between 
EFC and cisp caused a significant decrease in cell 
viability. This result indicates that EFC can be used 
in combination with cisp on HeLa cells.  
 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
  
(B)  
 
 
 
 
 
 
 
 
 
Figure 1.  Effects of EFC on cell viability and morphological changes on HeLa cells. (A) HeLa cells was treated using EFC (0,30-
90 μg/mL) for 24 h and determined by MTT assay as described in materials and methods. Data are representative of 
values from three independent experiments. (B) Morphological changes of HeLa cells were observed using binocular 
microscope. Viable cells (full arrow), morphological changes (dotted line), bars: 50 µM (magnification 100x) 
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Figure 2. Cytotoxic Effect of EFC was combined with cisp on HeLa cells. (A) HeLa cells were treated for 24 h with 
combination both of EFC and cisp caused decreasing percentage of cell viability. Cells viability were determined by 
MTT assay as described in materials and methods. (*) Significances (p<0.05). (B) Cells’ morphological changes 
treated with combination both of EFC 28 µg/ml and cisp (2, 4, 8 µM) were examined and photographed by 
binocular microscope. Viable cells (full arrow), morphological changes (dotted line), bars: 50 µM (magnification 
100x).   
 
 
Effect of EFC and Cisp on Cells Death 
Induction on HeLa Cells 
According to the cytotoxic combination 
between EFC and cisp mentioned below, cell death 
detection was carried out by flow cytometry using 
the less of IC50 concentration. Fig. 3 shows the effect 
of EFC, cisp and combination of both caused cell 
death induction. EFC could not increase cell death 
through apoptosis signal. However, it could increase 
necrosis cell death which was induced by 
combination of EFC and cisp compared to cisp-
single treatment. Cisp-single treatment and 
combination of cisp with EFC (24 h treatment) 
caused  82% and 72% cell death, respectively (Fig. 
3B). The apoptosis value of cisp-single treatment 
and its combination with EFC were 71.50% and 
40.41%, while the necrosis values were 10.38% and 
31.81%, respectively. EFC-single treatment caused 
less cell death induction with apoptosis value of 
5.85% and necrosis value of 2.38%. These results  
suggest that EFC may affect HeLa cells’ sensitivity 
to cisp which is caused by apoptosis and necrosis 
cell death. 
 
 
 
Cisp 2 µM -  + - +  - - -  - - - 
Cisp 4 µM -  - - -  + - +  - - - 
Cisp 8 µM -  - - -  - - -  + - + 
EFC 28 µg/ml -  - + +  - + +  - + + 
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(A)  
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cells death induction was caused by Cisp and its combination with EFC. (A) HeLa cells was treated 
with EFC 20 μg/mL, Cisp 8 μM, and both of it for 24 h. Then, Cells death was calculated by Flow cytometry 
assay using annexin V-FITC/PI staining. R1 viable, R2 early apoptotic, R3 late apoptotic, R3 necrotic cells. (B) 
Data was analyzed using Microsoft exel 2007 describing cell death percentage.   
 
 
Effect of EFC and Cisp on Cell Cycle 
Modulation of HeLa Cells  
Cell Cycle analysis by flow cytometry was 
used to evaluate the cell cycle distribution by EFC, 
cisp and combination of both. Cisp has been reported 
to induce cell cycle arrest in G2/M phase in some 
cancer cells
 
(Fehrmann and Laimins, 2003) and this 
study confirm that EFC induced cell cycle arrest in S 
phase. Cell distribution analysis was performed to 
investigate the effect of EFC addition to cisp on cell 
cycle arrest of HeLa cells. Fig. 4 shows HeLa cells 
treated with 28 µg/mL EFC, 8 µM cisp, and a 
combination of the two agents for 24 h. HeLa cells 
treated with EFC and cisp showed cells 
accumulation in S phase and G2/M phase, 
respectively. While combination of both agents 
caused redistribution of the cell cycle in G1 and S 
phase compared to cisp-treated cells. In addition, 
accumulation of cells in G2/M phase decreased 
compared to cisp-treated cells. These results above 
suggested that EFC enhances cytotoxicity induced 
by cisp on HeLa cells through cell cycle arrest in G1 
and S phase. The cells progression in G1 and S 
phase might be caused by some proteins that play a 
role in cell cycle checkpoints. 
 
 
 
 
EFC  (µg/mL) 0 20 0 20 
Cisp (µM) 0 0 8 8 
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Figure 4.  Cisp in combination with EFC caused cell cycle modulation on Hela cells. Cells were treated with 28 
μg/mL EFC, 8μM cisp and combination of both for 24 h. Cell cycle distribution was calculated by Flow cytometry 
then analyzed using ModFit LT 3.0. 
 
 
Expression of p53 was caused by EFC and 
Cisp on HeLa Cells 
To confirm the mechanism of EFC and its 
combination with cisp in cell cycle arrest, therefore 
molecular target protein p53 was investigated. HeLa 
cells performed degradation and function loss of p53 
as tumor suppressor protein which then cause 
uncontrolled proliferative cells
 
(Fehrmann and 
Laimins, 2003; Minaguchi, et al., 1998). As shown 
in Fig. 5, immunocytochemistry evaluation indicated 
that p53 level increased significantly (p<0.05) (Fig. 
5A) confirmed by an intensive brown color in 
nucleus after being treated with 28 µg/mL EFC-
single treatment and in combination with 8 µM cisp 
compared to cisp-single treatment and non-treated 
cells. The results suggest that EFC enhances cisp 
cytotoxicity on HeLa cells through p53 stabilization 
that perhaps play a role in cell cycle checkpoints. 
 
 
 
(A) 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Effect of EFC and Cisp on p53 expression of HeLa cells. (A)  HeLa cells were treated for 15 h with 28 µg/mL 
EFC, 8 µM cisp, and in combination of both. Data was examined and photographed by binocular microscope. Bars: 5 
µM (magnification 400x).  (B) Quantitative results showed analysis of p53 level in nucleus considered significantly 
different between combination treatment and single treatment (p<0.05).  
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DISCUSSION 
 
Ethyl acetate fraction of C. sappan (EFC) 
performed more potent cytotoxic effect on HeLa 
cells compared to ethanolic extract (320 µg/mL, data 
not shown), showing a concentration dependent 
manner, with IC50 of 65±1.5 µg/mL. Combination 
treatment of EFC and cisp at low concentration  
performed significant inhibition of cell viability 
compared to cisp-single treatment. A relatively low 
concentration was used to minimize the additional 
side effects and cellular resistance of cisp. 
Decreasing cells viability might be due to either cell 
death or cell cycle arrest. 
This study shows that combination of EFC 
and cisp treatment on HeLa cells induced more 
necrotic rate up to 31.81% compared to cisp-single 
treatment. Afterward, EFC-single treatment caused 
less apoptosis compared to cisp. Hence, cisp is 
possibly more responsible in inducing apoptosis than 
EFC and its combination with EFC. The 
combination between EFC and cisp may affect on 
cell cycle modulation that can cause a decrease in 
cell viability on HeLa cells. Cisp has been reported 
as anti-cancer agent by inducing G2/M phase arrest 
and apoptosis in some type of cancer cells (Jamieson 
and Lippard, 1999; Fehrmann and Laimins, 2003). 
Our results suggest that EFC enhanced HeLa cells’ 
sensitivity to cisp through cell cycle redistribution, 
causing arrest in G1 and S phase. Cell cycle arrest is 
related to the efficacy of cytotoxicity of 
chemotherapeutic agent being used. Previous studies 
reported chemo-sensitization of cancer cells by many 
chemotherapeutic drugs perhaps due to cell cycle 
modulation
 
(Lawrence, et al., 2003). Therefore, the 
delay of cell cycle distribution in G1 and S phase by 
EFC may be important in the sensitization of HeLa 
cells to cisp which causes a delay in G2/M phase. 
The experiments was continued to investigate the 
protein target on cell cycle by detecting the presence 
of p53.   
HeLa cells are characterized with p53 
degradation due to the binding of HPV E6 protein 
complexes to cellular factor E6AP which leads to 
ubiquitin-mediated degradation by proteasome 
(Buitrago-pérez, et al., 2009). EFC increased p53 
expression in nucleus and its combination with cisp 
significantly increased p53 expression compared to 
EFC and cisp-single treatment (Fig. 5). The p53 
protein activation may indirectly affect cellular 
response through some protein regulation causing 
cell cycle arrest to lead DNA repair or cell death 
activation (Jamieson and Lippard, 1999; Ricci and 
Zong, 2006; Schmitt, et al., 2002). These results 
suggested that the mechanism of EFC in sensitizing 
HeLa cells to cisp was possibly via p53-dependent. 
Brazilein as the main compound of C. sappan 
probably could inhibit HPV E6 interaction with E6-
binding protein E6AP. Therefore, brazilein may be 
amendable as HPV inhibitor agent and as competitor 
of vaccine to prevent the development of cervical 
cancer. However, this hypothesis still needs further 
investigation by in silico study.  
 
CONCLUSION 
 
In conclusion, EFC exhibits potential ability 
to enhance sensitivity of cervical cancer HeLa cells 
to cisp in vitro through cell cycle arrest with p53 
stabilization. Further molecular target detection to 
investigate its cellular pathway needs to be 
conducted. 
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